Contact
searchSearch
HMP Global

Ankylosing Spondylitis

Featured Article

News
Opioid Use Associated With Fractures in People With Ankylosing Spondylitis
12/20/2023
Lisa Kuhns, PhD, MD
Increasing age, historical fracture, and opioid use are associated with higher odds of fracture in ankylosing spondylitis (AS), according to a study published in Arthritis Care & Research. “We performed a retrospective cohort study...
Increasing age, historical fracture, and opioid use are associated with higher odds of fracture in ankylosing spondylitis (AS), according to a study published in Arthritis Care & Research. “We performed a retrospective cohort study...
Increasing age, historical...
12/20/2023
First Report Managed Care
News
Analysis Finds Similar Safety Profile with Upadacitinib Across Conditions
11/03/2023
Jolynn Tumolo
The Janus kinase (JAK) inhibitor upadacitinib offers a similar long-term safety profile across rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and atopic dermatitis (AD) despite some variations in adverse...
The Janus kinase (JAK) inhibitor upadacitinib offers a similar long-term safety profile across rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and atopic dermatitis (AD) despite some variations in adverse...
The Janus kinase (JAK) inhibitor...
11/03/2023
First Report Managed Care
News
High Rates of Depression, Anxiety in Patients With Ankylosing Spondylitis
10/06/2023
Jolynn Tumolo
Half of patients with ankylosing spondylitis had clinically significant depression, and more than a third had clinically significant anxiety, according to a single-center, cross-sectional study currently underway.
Half of patients with ankylosing spondylitis had clinically significant depression, and more than a third had clinically significant anxiety, according to a single-center, cross-sectional study currently underway.
Half of patients with ankylosing...
10/06/2023
First Report Managed Care
News
Achieving Disease Control in PsA, AS Associated with Lower Medical Costs
09/15/2023
Jolynn Tumolo
A study published in Rheumatology and Therapy found that individuals diagnosed with psoriatic arthritis (PsA) or ankylosing spondylitis (AS) and exhibiting lower levels of disease activity incurred reduced healthcare resource utilization and...
A study published in Rheumatology and Therapy found that individuals diagnosed with psoriatic arthritis (PsA) or ankylosing spondylitis (AS) and exhibiting lower levels of disease activity incurred reduced healthcare resource utilization and...
A study published in...
09/15/2023
First Report Managed Care
News
Can Tumor Necrosis Factor Inhibitors Reduce the Risk of Fractures in AS Patients?
08/30/2023
Danielle Sposato
Researchers sought to understand if fracture risk decreased among individuals with ankylosing spondylitis with tumor necrosis factor inhibitors treatments compared to non-AS patients.
Researchers sought to understand if fracture risk decreased among individuals with ankylosing spondylitis with tumor necrosis factor inhibitors treatments compared to non-AS patients.
Researchers sought to understand...
08/30/2023
First Report Managed Care
News
Fear of Movement in Patients With Ankylosing Spondylitis Linked With Lower Life Quality
07/27/2023
Jolynn Tumolo
Research findings indicate a link between kinesiophobia, a fear of movement and injury, and decreased quality of life in patients with ankylosing spondylitis.
Research findings indicate a link between kinesiophobia, a fear of movement and injury, and decreased quality of life in patients with ankylosing spondylitis.
Research findings indicate a...
07/27/2023
First Report Managed Care
News
Tildrakizumab No Better Than Placebo for Ankylosing Spondylitis
06/09/2023
Jolynn Tumolo
A 48-week trial of tildrakizumab in patients with ankylosing spondylitis was terminated early after researchers found that the drug had no efficacy in comparison to placebo.
A 48-week trial of tildrakizumab in patients with ankylosing spondylitis was terminated early after researchers found that the drug had no efficacy in comparison to placebo.
A 48-week trial of tildrakizumab...
06/09/2023
First Report Managed Care
News
Risk of Psychiatric Comorbidity Higher in Patients With Ankylosing Spondylitis
05/19/2023
Jolynn Tumolo
Findings from a population-based, cross-sectional study suggest that patients with ankylosing spondylitis are at a higher risk of developing psychiatric disorders.
Findings from a population-based, cross-sectional study suggest that patients with ankylosing spondylitis are at a higher risk of developing psychiatric disorders.
Findings from a...
05/19/2023
First Report Managed Care
News
Short-term Biosimilar Adalimumab Provides Long-term Relief for Ankylosing Spondylitis
04/14/2023
Jolynn Tumolo
Treatment with biosimilar adalimumab was associated with a significant improvement in ankylosing spondylitis symptoms for up to 1 year, according to new findings.
Treatment with biosimilar adalimumab was associated with a significant improvement in ankylosing spondylitis symptoms for up to 1 year, according to new findings.
Treatment with biosimilar...
04/14/2023
First Report Managed Care
News
JAK Inhibitor Improves Slate of Patient-Reported Outcomes in Biologic Refractory Ankylosing Spondylitis
03/28/2023
Jolynn Tumolo
Researchers studied a JAK inhibitor's efficacy for improving disease activity, health-related quality of life, and other measures in a cohort of patients with ankylosing spondylitis who did not respond or tolerate biologics.
Researchers studied a JAK inhibitor's efficacy for improving disease activity, health-related quality of life, and other measures in a cohort of patients with ankylosing spondylitis who did not respond or tolerate biologics.
Researchers studied a JAK...
03/28/2023
First Report Managed Care
News
Baseline Variables Predict Probability of Initial Response to TNFi Inhibitors in Patients With AS
10/27/2022
Edan Stanley
Researchers sought to develop models of the probability of short-term response to tumor necrosis factor inhibitor treatment in patients with ankylosing spondylitis.
Researchers sought to develop models of the probability of short-term response to tumor necrosis factor inhibitor treatment in patients with ankylosing spondylitis.
Researchers sought to develop...
10/27/2022
First Report Managed Care

Newsfeed

News
Opioid Use Associated With Fractures in People With Ankylosing Spondylitis
12/20/2023
Lisa Kuhns, PhD, MD
Increasing age, historical fracture, and opioid use are associated with higher odds of fracture in ankylosing spondylitis (AS), according to a study published in Arthritis Care & Research. “We performed a retrospective cohort study...
Increasing age, historical fracture, and opioid use are associated with higher odds of fracture in ankylosing spondylitis (AS), according to a study published in Arthritis Care & Research. “We performed a retrospective cohort study...
Increasing age, historical...
12/20/2023
First Report Managed Care
News
Analysis Finds Similar Safety Profile with Upadacitinib Across Conditions
11/03/2023
Jolynn Tumolo
The Janus kinase (JAK) inhibitor upadacitinib offers a similar long-term safety profile across rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and atopic dermatitis (AD) despite some variations in adverse...
The Janus kinase (JAK) inhibitor upadacitinib offers a similar long-term safety profile across rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and atopic dermatitis (AD) despite some variations in adverse...
The Janus kinase (JAK) inhibitor...
11/03/2023
First Report Managed Care
News
High Rates of Depression, Anxiety in Patients With Ankylosing Spondylitis
10/06/2023
Jolynn Tumolo
Half of patients with ankylosing spondylitis had clinically significant depression, and more than a third had clinically significant anxiety, according to a single-center, cross-sectional study currently underway.
Half of patients with ankylosing spondylitis had clinically significant depression, and more than a third had clinically significant anxiety, according to a single-center, cross-sectional study currently underway.
Half of patients with ankylosing...
10/06/2023
First Report Managed Care
News
Achieving Disease Control in PsA, AS Associated with Lower Medical Costs
09/15/2023
Jolynn Tumolo
A study published in Rheumatology and Therapy found that individuals diagnosed with psoriatic arthritis (PsA) or ankylosing spondylitis (AS) and exhibiting lower levels of disease activity incurred reduced healthcare resource utilization and...
A study published in Rheumatology and Therapy found that individuals diagnosed with psoriatic arthritis (PsA) or ankylosing spondylitis (AS) and exhibiting lower levels of disease activity incurred reduced healthcare resource utilization and...
A study published in...
09/15/2023
First Report Managed Care
News
Can Tumor Necrosis Factor Inhibitors Reduce the Risk of Fractures in AS Patients?
08/30/2023
Danielle Sposato
Researchers sought to understand if fracture risk decreased among individuals with ankylosing spondylitis with tumor necrosis factor inhibitors treatments compared to non-AS patients.
Researchers sought to understand if fracture risk decreased among individuals with ankylosing spondylitis with tumor necrosis factor inhibitors treatments compared to non-AS patients.
Researchers sought to understand...
08/30/2023
First Report Managed Care
News
Fear of Movement in Patients With Ankylosing Spondylitis Linked With Lower Life Quality
07/27/2023
Jolynn Tumolo
Research findings indicate a link between kinesiophobia, a fear of movement and injury, and decreased quality of life in patients with ankylosing spondylitis.
Research findings indicate a link between kinesiophobia, a fear of movement and injury, and decreased quality of life in patients with ankylosing spondylitis.
Research findings indicate a...
07/27/2023
First Report Managed Care
News
Tildrakizumab No Better Than Placebo for Ankylosing Spondylitis
06/09/2023
Jolynn Tumolo
A 48-week trial of tildrakizumab in patients with ankylosing spondylitis was terminated early after researchers found that the drug had no efficacy in comparison to placebo.
A 48-week trial of tildrakizumab in patients with ankylosing spondylitis was terminated early after researchers found that the drug had no efficacy in comparison to placebo.
A 48-week trial of tildrakizumab...
06/09/2023
First Report Managed Care
News
Risk of Psychiatric Comorbidity Higher in Patients With Ankylosing Spondylitis
05/19/2023
Jolynn Tumolo
Findings from a population-based, cross-sectional study suggest that patients with ankylosing spondylitis are at a higher risk of developing psychiatric disorders.
Findings from a population-based, cross-sectional study suggest that patients with ankylosing spondylitis are at a higher risk of developing psychiatric disorders.
Findings from a...
05/19/2023
First Report Managed Care
News
Short-term Biosimilar Adalimumab Provides Long-term Relief for Ankylosing Spondylitis
04/14/2023
Jolynn Tumolo
Treatment with biosimilar adalimumab was associated with a significant improvement in ankylosing spondylitis symptoms for up to 1 year, according to new findings.
Treatment with biosimilar adalimumab was associated with a significant improvement in ankylosing spondylitis symptoms for up to 1 year, according to new findings.
Treatment with biosimilar...
04/14/2023
First Report Managed Care
News
JAK Inhibitor Improves Slate of Patient-Reported Outcomes in Biologic Refractory Ankylosing Spondylitis
03/28/2023
Jolynn Tumolo
Researchers studied a JAK inhibitor's efficacy for improving disease activity, health-related quality of life, and other measures in a cohort of patients with ankylosing spondylitis who did not respond or tolerate biologics.
Researchers studied a JAK inhibitor's efficacy for improving disease activity, health-related quality of life, and other measures in a cohort of patients with ankylosing spondylitis who did not respond or tolerate biologics.
Researchers studied a JAK...
03/28/2023
First Report Managed Care
News
Medicaid Coverage Remains Suboptimal After Medicare Enrollment
08/03/2026
Rebecca Amrick
A study found that waiving the Medicare Savings Program (MSP) asset test could help newly enrolled Medicare beneficiaries retain Medicaid coverage, but variations in state-level coverage and suboptimal rates of enrollment raise concerns about...
A study found that waiving the Medicare Savings Program (MSP) asset test could help newly enrolled Medicare beneficiaries retain Medicaid coverage, but variations in state-level coverage and suboptimal rates of enrollment raise concerns about...
A study found that waiving the...
08/03/2026
First Report Managed Care
Behind the Bill
Court Challenge Tests CMS' New Medicaid Work Requirement Rule
07/31/2026
Hannah Musick
A federal court has allowed CMS' new Medicaid work requirement rule to move forward while a multistate legal challenge continues, setting the stage for a broader debate over how the landmark eligibility changes will be implemented nationwide.
A federal court has allowed CMS' new Medicaid work requirement rule to move forward while a multistate legal challenge continues, setting the stage for a broader debate over how the landmark eligibility changes will be implemented nationwide.
A federal court has allowed CMS'...
07/31/2026
First Report Managed Care
News
GLP-1 RAs Have Higher Utilization Among Patients With Obesity Than Bariatric Surgery
07/28/2026
Rebecca Amrick
A study found that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are the more common treatment option for obesity among adolescents and young adults compared to bariatric surgery.
A study found that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are the more common treatment option for obesity among adolescents and young adults compared to bariatric surgery.
A study found that glucagon-like...
07/28/2026
First Report Managed Care
News
Kidney Transplant Referrals Show Significant Attrition Before Waitlisting
07/28/2026
Grace Taylor, MS, MA
A large US electronic health record analysis found that only 1 in 10 patients referred for kidney transplantation ultimately received a transplant, highlighting substantial attrition before waitlisting and identifying key patient- and...
A large US electronic health record analysis found that only 1 in 10 patients referred for kidney transplantation ultimately received a transplant, highlighting substantial attrition before waitlisting and identifying key patient- and...
A large US electronic health...
07/28/2026
First Report Managed Care
News
Insurance Coverage Impacts Episode of Care for Spinal Fusions
07/27/2026
Rebecca Amrick
A study found that among patients who underwent lumbar fusions, those covered by Medicare Advantage had longer lengths of stay and higher rates of home discharges than those covered by Medicare Fee-For-Service, illustrating gaps in episode of...
A study found that among patients who underwent lumbar fusions, those covered by Medicare Advantage had longer lengths of stay and higher rates of home discharges than those covered by Medicare Fee-For-Service, illustrating gaps in episode of...
A study found that among...
07/27/2026
First Report Managed Care
News
US Study Identifies Factors Linked to Low Metabolic Bariatric Surgery Uptake
07/24/2026
Grace Taylor, MS, MA
A large US cohort study found that only 3% of adults newly diagnosed with obesity underwent metabolic bariatric surgery within one year, with provider type, body mass index, sex, and other clinical factors strongly influencing access to...
A large US cohort study found that only 3% of adults newly diagnosed with obesity underwent metabolic bariatric surgery within one year, with provider type, body mass index, sex, and other clinical factors strongly influencing access to...
A large US cohort study found...
07/24/2026
First Report Managed Care
Behind the Bill
Federal Court Pauses Key ACA Marketplace Rule Changes
07/23/2026
Hannah Musick
A federal court has temporarily blocked several key provisions of Centers for Medicare & Medicaid Services' (CMS') 2027 Affordable Care Act (ACA) Marketplace rule, setting up a high-stakes legal battle over federal authority, Marketplace...
A federal court has temporarily blocked several key provisions of Centers for Medicare & Medicaid Services' (CMS') 2027 Affordable Care Act (ACA) Marketplace rule, setting up a high-stakes legal battle over federal authority, Marketplace...
A federal court has temporarily...
07/23/2026
First Report Managed Care
News
CMS Proposes New Medicaid Provider Tax Thresholds Under WFTC Legislation
07/23/2026
Grace Taylor, MS, MA
The Centers for Medicare & Medicaid Services (CMS) has proposed sweeping changes to Medicaid provider tax regulations that would establish new indirect hold harmless thresholds, expand reporting requirements, and reshape state health...
The Centers for Medicare & Medicaid Services (CMS) has proposed sweeping changes to Medicaid provider tax regulations that would establish new indirect hold harmless thresholds, expand reporting requirements, and reshape state health...
The Centers for Medicare &...
07/23/2026
First Report Managed Care
News
Fabhalta (Iptacopan) Receives FDA Approval to Slow Disease Progression in Patients With IgAN
07/22/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) recently approved Fabhalta (iptacopan) to slow kidney function decline in patients with immunoglobulin A nephropathy (IgAN).
The US Food and Drug Administration (FDA) recently approved Fabhalta (iptacopan) to slow kidney function decline in patients with immunoglobulin A nephropathy (IgAN).
The US Food and Drug...
07/22/2026
First Report Managed Care
News
Obesity Subphenotype With Low GLP-1 Levels Shows Greater Weight Loss With Tirzepatide
07/21/2026
Hannah Musick
Researchers identified an obesity subphenotype characterized by rapid gastric emptying and low endogenous GLP-1 production that achieved nearly twice the weight loss with tirzepatide as other obesity phenotypes, highlighting the potential for...
Researchers identified an obesity subphenotype characterized by rapid gastric emptying and low endogenous GLP-1 production that achieved nearly twice the weight loss with tirzepatide as other obesity phenotypes, highlighting the potential for...
Researchers identified an...
07/21/2026
First Report Managed Care

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use